NEW YORK, April 29, 2021 / PRNewswire / – Adjuvant capital, a life sciences investment firm focused on global health, today announced that Phillipe dro, Pharm. D., MBA, will join as a partner and be based in Zurich, Switzerland. As an entrepreneur and seasoned executive in the field of biopharmacy and medical devices with more than 25 years of experience, Dr Dro brings to the Adjuvant Capital team significant operational, scientific, technical and development expertise. of products. He is currently Chairman of the Board of Directors of AmsterdamBased on Scenic Biotech, as well as Swiss companies, Luciole Medical and LimmaTech Biologics.
“We are delighted to welcome someone of Philippe’s caliber to the Adjuvant team,” said Glenn rockman, managing partner at Adjuvant Capital. “With decades of leadership in the life science and medical device industries as CEO, founder and investor, Philippe will play an important role in expanding Adjuvant’s presence and investment activities across Europe. “
Most recently, Dr Dro was a member of the Board of Directors and Chief Commercial Officer (CBO) of Themis, an Austrian biotechnology company focused on vaccine development, until its acquisition by Merck & Co. (known as from MSD outside United States). He was also CEO and member of the supervisory board of Swiss company GlycoVaxyn AG, leading it through its acquisition by GSK in 2015. Earlier in his career, Mr. Dro was Chairman and CEO of Endoart SA, a medical technology company led a corporate turnaround that culminated in its acquisition by Allergan. He was part of the founding team of a G protein coupled receptor (GPCR) biotechnology company, Axovan, which was acquired by Actelion in 2003. Dr Dro previously worked in the pharmaceutical industry, where he worked held various operational and management positions at Novartis, SkyePharma and Antares Pharma.
“Adjuvant occupies a truly unique and disruptive position in supporting companies and technologies that address significant global health challenges with the discipline and focus of a venture capital fund,” added Dr Dro. . “I believe that the potential impact of such an approach can be huge for the company, as well as for investors. I am very happy to work with the Adjuvant team and share their vision of growing companies that will directly benefit underserved populations. “
About Adjuvant Capital
Based at new York, with offices in San Francisco and Zurich, Adjuvant is a global life sciences investment company designed to accelerate the development of new technologies to address the world’s most pressing public health challenges. Backed by leading healthcare and emerging market investors, Adjuvant draws on its global network of scientists, public health experts, biopharmaceutical industry veterans and development finance professionals to identify new investment opportunities. Adjuvant invests in companies developing promising new vaccines, therapeutics, diagnostics and medical devices targeting high-burden infectious diseases, maternal and child health, antimicrobial resistance and malnutrition, with a commitment to make these interventions accessible to those who need it. need it most in middle-income countries. For more information visit adjuvantcapital.com.
This document is for informational purposes only and is not intended to be investment advice, an offer or a solicitation regarding the purchase or sale of any security, including a participation in an investment fund managed by Adjuvant. Holdings in such a fund are not registered with any regulatory authority, are offered under exemptions from such registration and are offered exclusively to certain eligible investors in accordance with the applicable fund offering documents. The testimonials included in this document are provided by people invested in Adjuvant Capital who have agreed to provide comments and are not directly or indirectly remunerated by Adjuvant Capital to do so.
SOURCE Adjuvant Capital